| Title |
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
|
|---|---|
| Published in |
Investigational New Drugs, December 2013
|
| DOI | 10.1007/s10637-013-0047-4 |
| Pubmed ID | |
| Authors |
E. M. Dunbar, B. S. Coats, A. L. Shroads, T. Langaee, A. Lew, J. R. Forder, J. J. Shuster, D. A. Wagner, P. W. Stacpoole |
| Abstract |
Recurrent malignant brain tumors (RMBTs) carry a poor prognosis. Dichloroacetate (DCA) activates mitochondrial oxidative metabolism and has shown activity against several human cancers. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 33% |
| Canada | 1 | 17% |
| United States | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Unknown | 132 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 25 | 19% |
| Researcher | 22 | 17% |
| Student > Bachelor | 16 | 12% |
| Student > Doctoral Student | 11 | 8% |
| Student > Master | 10 | 8% |
| Other | 20 | 15% |
| Unknown | 29 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 24% |
| Biochemistry, Genetics and Molecular Biology | 20 | 15% |
| Agricultural and Biological Sciences | 18 | 14% |
| Chemistry | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Other | 15 | 11% |
| Unknown | 34 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2023.
All research outputs
#1,929,066
of 24,503,376 outputs
Outputs from Investigational New Drugs
#36
of 1,238 outputs
Outputs of similar age
#21,901
of 317,987 outputs
Outputs of similar age from Investigational New Drugs
#2
of 13 outputs
Altmetric has tracked 24,503,376 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,238 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,987 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.